EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Drug development studies supporting zileuton as a parenteral adjuvant to attenuate antibiotic-associated nephrotoxicity

Cole S Hudson, James E Smith, Linh T Vuong, Nicholas S Teran, Nazanin Pouya, David Sheikh-Hamad, Xinli Liu, Shama Kajiji, Vincent H Tam iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00287-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Cole S Hudson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacological & Pharmaceutical Sciences, University of Houston College of Pharmacy, Houston, Texas, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Kidney, Hydroxyurea, Kidney Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NIAID NIH HHS, VA Merit award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glycopeptide, polymyxin, and aminoglycoside antibiotics are among the most commonly used agents to treat drug-resistant bacterial infections; however, their clinical use is hindered by nephrotoxicity. We previously reported that zileuton has the potential to attenuate antibiotic-associated nephrotoxicity in an animal model. Here, we further report the development of a parenteral formulation and exploration of dosing strategies for zileuton. The solubility, stability, and multi-dose safety of two zileuton formulations were evaluated. Zileuton serum and renal tissue pharmacokinetics were evaluated after a single dose and compared to steady state after 10 days. Different dosing strategies of zileuton to attenuate vancomycin-, polymyxin B-, and amikacin-associated nephrotoxicity were evaluated in rats over 10 days. Two formulations (1 and 10 mg/mL) showed good multi-dose safety, with no significant changes in serum creatinine, alanine transaminase, or body weight observed following doses of 12 mg/kg daily for 10 days. Zileuton was well-distributed into renal tissue, and serum exposure was comparable to humans after a typical dose (600–2,400 mg). No drug accumulation at steady state was observed. Zileuton was found to reduce nephrotoxicity associated with vancomycin, polymyxin B, and amikacin in a dose-dependent manner. With the same daily dose, dose fractionation resulted in similar renal protection compared to once-daily dosing. These preliminary studies support that zileuton has the potential to be used as a parenteral adjuvant to attenuate antibiotic-associated nephrotoxicity. This would allow the optimal use of glycopeptides, polymyxins, and aminoglycosides to treat difficult infections. Further studies are warranted to repurpose zileuton as a nephroprotectant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsKidneyHydroxyureaKidney DiseasesAnimalsRatsMaleVancomycinRats, Sprague-DawleyDrug DevelopmentAmikacinCreatinine

Stichwörter der Autor:innen

antimicrobial resistancedrug formulationnephroprotectant

Substanzen

Anti-Bacterial AgentsVancomycinHydroxyureazileutonAmikacinCreatinine

Autor:innen und Institutionen

  • Department of Pharmacological & Pharmaceutical Sciences, University of Houston College of Pharmacy, Houston, Texas, USA.
  • Department of Pharmacy Practice & Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA.
  • Division of Nephrology and Selzman Institute for Kidney Health, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Center for Translational Research on Inflammatory Diseases (CTRID), Michael E DeBakey VA Medical Center, Houston, Texas, USA.
  • Emergent System Analytics, LLC, Clinton, Connecticut, USA.

ORCID-Profile: Vincent H Tam

Förderung

  • BLRD VA
  • NIAID NIH HHS
  • VA Merit award
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Hudson, C. S., Smith, J. E., Vuong, L. T., Teran, N. S., Pouya, N., Sheikh-Hamad, D., Liu, X., Kajiji, S., & Tam, V. H. (2025). Drug development studies supporting zileuton as a parenteral adjuvant to attenuate antibiotic-associated nephrotoxicity. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00287-25

Vancouver

Hudson CS, Smith JE, Vuong LT, Teran NS, Pouya N, Sheikh-Hamad D, et al. Drug development studies supporting zileuton as a parenteral adjuvant to attenuate antibiotic-associated nephrotoxicity. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00287-25

BibTeX
@article{Hudson2025,
  author = {Hudson, Cole S and Smith, James E and Vuong, Linh T and Teran, Nicholas S and Pouya, Nazanin and Sheikh-Hamad, David and Liu, Xinli and Kajiji, Shama and Tam, Vincent H},
  title = {Drug development studies supporting zileuton as a parenteral adjuvant to attenuate antibiotic-associated nephrotoxicity},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00287-25}
}
Kostenlos starten →